Key result
Cyclin D and cell cycle proteins regulate LVH and represent attractive targets for HF.
Cyclin D and related cell cycle regulatory pathways represent potential therapeutic targets for the treatment of left ventricular hypertrophy and heart failure.
May guide novel heart failure therapies targeting cell cycle proteins; leaves open clinical translation pending trials.
Left ventricle hypertrophy is induced by a number of stimuli and can lead to cardio-myopathy and heart failure. The hypertrophic response is achieved by enlargement of the cardiac myocytes and is regulated by multiple signaling pathways, with the D-type cyclins playing a crucial role. Induction of cyclin D in adult cardiac myocytes leads to activation of cyclin-dependent kinases 4 and 6 and a partial progress through the cell cycle. Therefore, these pathways are attractive therapeutic target for treatment of heart failure and hypertrophy. We discuss the activity of cyclin D and other cell cycle regulatory proteins in left ventricle hypertrophy and whether the hypertrophic signaling pathways converge at the D-type cyclins.
No takes yet. Share an insight, caveat, or question.
Busk et al. (2003) conducted a review in Left ventricle hypertrophy. Cyclin D and other cell cycle regulatory proteins play a crucial role in left ventricle hypertrophy and represent attractive therapeutic targets for heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: